<DOC>
	<DOCNO>NCT02046486</DOCNO>
	<brief_summary>This single-center , prospective , randomize , single-blind , investigator initiate , pharmacokinetic/pharmacodynamic study parallel design.Patients ST elevation myocardial infarction ( symptom onset &lt; 12 hour ) , undergo primary percutaneous coronary intervention , P2Y12 inhibitor naïve , randomize informed consent , immediately diagnostic coronary angiography , 1:1 ratio either : - Ticagrelor 180mg loading dose , form 2 whole tablet administer per o supine position ( standard administration ) - Ticagrelor 180mg load dose , form 2 tablet crush dispersed purified water administer per os 1-minute-stay 60-70 degree semi-upright sit position Platelet reactivity assessment perform randomization ( Hour 0 ) 0.5 , 1 , 2 , 4 6 hour randomization , use VerifyNow assay , platelet reactivity unit ( PRU ) . The cutoff &gt; 208 PRU use definition high platelet reactivity ( HPR ) . All platelet reactivity assessment perform physician blind actual treatment give . Additional blood sample collect time point pharmacokinetic analysis . These sample collect vacuum tube lithium heparin keep ice centrifugation ( 3000 rpm 4°C 10 min , within 30 min sample ) . The resultant plasma transfer plain polypropylene tube ( screw cap ) store -20°C analyse .</brief_summary>
	<brief_title>OraL Crushed dIspersed Ticagrelor 180mg Compared Whole Tablets eQUal Dose STEMI Patients unDergoing Primary PCI : Pharmacokinetic/Pharmacodynamic Study ( LIQUID Study )</brief_title>
	<detailed_description>Preparation Ticagrelor liquid formulation : Crushed disperse Ticagrelor 180mg oral administration prepare follow : two ticagrelor 90mg tablet place mortar crush 60 use pestle . 20 mL purify water add mortar stir 60 . The liquid transfer dosing cup another 15 mL purify water add mortar stir , ensure powder disperse none remain mortar pestle . Again liquid transfer dosing cup . The procedure repeat 15 ml purify water.The total content stir another 30 ensure remain tablet particle disperse .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age ≥18 year old 2 . Patients STEMI ( onset pain &lt; 12 hour ) indication primary PCI 3 . Informed consent obtain write Pregnancy/Breastfeeding Severe nausea vomit Treatment P2Y12 inhibitor within previous 1 month Inability give inform consent Hemodynamic instability Arrhythmias require cardioversion , temporary pacemaker insertion intravenous antiarrhythmic agent Killip class ≥3 Known hypersensitivity ticagrelor History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 3 month . Other bleed diathesis , consider investigator high risk bleed Thombocytopenia ( &lt; 100.000 / μL ) randomization Anaemia ( Hct &lt; 30 % ) randomization Polycytaemia ( Hct &gt; 52 % ) randomization Periprocedural IIb/IIIa inhibitor administration Thrombolysis administration Recent ( &lt; 6 week ) major surgery trauma , include GABG . Concomitant oral IV therapy strong CY P3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazana vir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3A inducer ( rifampin /rifampicin , phenytoin , carbamazepine ) . Patients consider investigator increase risk bradycardiac event . Dialysis require . Severe uncontrolled chronic obstructive pulmonary disease Known severe hepatic impairement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>ST elevation myocardial infarction</keyword>
	<keyword>liquid formulation</keyword>
</DOC>